Search results for "MESH : Time Factors"

showing 10 items of 14 documents

Molecular phylogeny of the extinct giant deer, Megaloceros giganteus.

2006

a Centre de Genetique Moleculaire et Cellulaire (CGMC), CNRS UMR 5534, Universite Claude Bernard Lyon 1, Villeurbanne, France b Laboratoire d’Anthropologie des Populations du Passe, CNRS UMR 5199 PACEA, Universite Bordeaux 1, Talence, France c UCD School of Biology and Environmental Science, UCD, BelWeld, Dublin 4, Ireland d Laboratoire d’Ecologie des Hydrosystemes Fluviaux, CNRS UMR 5023, Universite Claude Bernard Lyon 1, Villeurbanne, France e Biogeosciences-Dijon, CNRS UMR 5561, Universite de Bourgogne, Centre des Sciences de la Terre, Dijon, France f Department of Palaeontology, Royal Belgian Institute of Natural Sciences, Brussels, Belgium g Department of Biology, University College Lo…

0106 biological sciencesTime FactorsMESH: GeographyMESH: Base Sequence[SDV.BID.SPT]Life Sciences [q-bio]/Biodiversity/Systematics Phylogenetics and taxonomy01 natural sciencesMESH: FossilsMESH : BiodiversityMESH: AnimalsMESH: PhylogenyGiant deerPhylogenyComputingMilieux_MISCELLANEOUS[ SDU.STU.PG ] Sciences of the Universe [physics]/Earth Sciences/Paleontology0303 health sciencesbiologyAncient DNAGeographyEcologymtDNAFossils[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]MegalocerosMESH : GeographyClaude bernardBiodiversityMESH : Deer[ SDV.GEN.GPO ] Life Sciences [q-bio]/Genetics/Populations and Evolution [q-bio.PE][SDU.STU.PG]Sciences of the Universe [physics]/Earth Sciences/PaleontologyMESH : Time Factors[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]MESH: Deer010603 evolutionary biologyMESH: BiodiversityQuaternary03 medical and health sciencesGeneticsAnimals14. Life underwaterMolecular BiologyEcology Evolution Behavior and Systematics030304 developmental biologyBase SequenceDeerMESH: Time FactorsMESH : Phylogenybiology.organism_classificationMESH : FossilsMESH : Base SequenceMESH : AnimalsHumanities[ SDV.BID.SPT ] Life Sciences [q-bio]/Biodiversity/Systematics Phylogenetics and taxonomy
researchProduct

Medium-size droplets of methyl ricinoleate are reduced by cell-surface activity in the gamma-decalactone production by Yarrowia lipolytica.

2000

International audience; Size of methyl ricinoleate droplets during biotransformation into gamma-decalactone by Yarrowia lipolytica was measured in both homogenized and non-homogenized media. In non-homogenized but shaken medium, droplets had an average volume surface diameter d32 of 2.5 microm whereas it was 0.7 microm in homogenized and shaken medium. But as soon as yeast cells were inoculated, both diameters became similar at about 0.7 microm and did not vary significantly until the end of the culture. The growth of Y. lipolytica in both media was very similar except for the lag phase which was lowered in homogenized medium conditions.

0106 biological sciences[SDV.BIO]Life Sciences [q-bio]/BiotechnologyTime FactorsCell01 natural sciencesApplied Microbiology and BiotechnologyLactonesBiotransformationMESH : Particle SizeYeastsMESH: Microscopy Confocal[INFO.INFO-BT]Computer Science [cs]/BiotechnologyComputingMilieux_MISCELLANEOUSBiotransformation0303 health sciencesMicroscopyMicroscopy ConfocalbiologyMESH: YeastsMESH : Lactones[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologymedicine.anatomical_structureBiochemistryConfocalSURFACE ACTIVERicinoleic Acids[ INFO.INFO-BT ] Computer Science [cs]/BiotechnologyMESH: LactonesMESH : Time Factors03 medical and health sciencesMESH : Biotransformation010608 biotechnologymedicine[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular Biology[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH: Particle SizeParticle SizeMESH : Microscopy Confocal[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyMethyl ricinoleateMESH: BiotransformationMESH : YeastsChromatography030306 microbiologyMESH: Time Factors[ SDV.BIO ] Life Sciences [q-bio]/BiotechnologyYarrowiabiology.organism_classificationYeastMESH: Ricinoleic AcidsCulture Media[SDV.BIO] Life Sciences [q-bio]/Biotechnology[INFO.INFO-BT] Computer Science [cs]/BiotechnologyMESH : Ricinoleic AcidsMESH: Culture MediaMESH : Culture Media
researchProduct

Effect of oxidative stress on UDP-glucuronosyltransferases in rat astrocytes.

2012

WOS:000309170300003; International audience; The present work reports data regarding effects of an induced oxidative stress on the mainly expressed isoforms of UDP-glucuronosyltransferases (UGTs) in the brain. UGT1A6 and UGT1A7 expression and enzymatic activities toward the 1-naphthol were analyzed in rat cultured astrocytes following the exposure for 48 h to redox-cycling xenobiotic compounds such as quinones and bipyridinium ions. The expression of NADPH:cytochrome P450 reductase and NAD(P)H:quinone oxidoreductase 1 (NQO1) was also investigated. Oxidative stress induced significant deleterious changes in astrocyte morphology, decreased cell viability and inhibited catalytic function of UG…

MESH : Oxidative StressMESH : RNA MessengerAntioxidantTranscription Geneticmedicine.medical_treatmentToxicologyNAD(P)H:quinone oxidoreductase 1MESH: GlucuronosyltransferaseAntioxidantsSubstrate SpecificityRats Sprague-Dawley0302 clinical medicineMESH: NADPH-Ferrihemoprotein ReductaseMESH: GlucuronidesNAD(P)H Dehydrogenase (Quinone)MESH : CatalysisMESH: AnimalsMESH : NAD(P)H Dehydrogenase (Quinone)GlucuronosyltransferaseCells Culturedchemistry.chemical_classificationMESH : Cell Survival0303 health sciencesMESH : Substrate SpecificityMESH : Animals NewbornCytochrome P450 reductaseGeneral MedicineMESH: Cell SurvivalMESH: Pyridinium CompoundsMESH : AntioxidantsMESH: Cells CulturedOxidative phosphorylationGene Expression Regulation EnzymologicMESH : QuinonesMESH : Glucuronides03 medical and health sciencesRNA MessengerCell ShapeNADPH-Ferrihemoprotein ReductaseMESH : Oxidation-ReductionMESH : Pyridinium CompoundsMESH: NaphtholsMESH : GlucuronosyltransferaseMESH: AntioxidantsMESH: CatalysischemistryOxidative stressAstrocytesReactive Oxygen Species030217 neurology & neurosurgeryMESH: Oxidation-ReductionTime Factors[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionMESH : Reactive Oxygen SpeciesNADPH:cytochrome P450 reductasePyridinium CompoundsNaphtholsMESH: Rats Sprague-DawleyProtein oxidationmedicine.disease_causeMESH: Animals NewbornMESH: NAD(P)H Dehydrogenase (Quinone)Protein CarbonylationMESH : OxidantsMESH: OxidantsMelatoninMESH: MelatoninMESH: Oxidative StressMESH : MelatoninMESH : RatsMESH: Gene Expression Regulation EnzymologicQuinonesMESH: Reactive Oxygen SpeciesOxidantsBiochemistryMESH : Protein CarbonylationOxidation-ReductionUDP-glucuronosyltransferaseMESH : Time FactorsMESH: Protein CarbonylationMESH: RatsCell SurvivalMESH : NaphtholsBiologyCatalysisMESH: QuinonesMESH : Gene Expression Regulation EnzymologicGlucuronidesMESH : Cells CulturedmedicineAnimalsMESH: Cell Shape030304 developmental biologyMESH: RNA MessengerReactive oxygen speciesMESH: Transcription GeneticMESH: Time FactorsMESH : AstrocytesMESH : Transcription GeneticNAD(P)H Dehydrogenase (Quinone)MESH : Rats Sprague-DawleyRatsMESH: AstrocytesAnimals NewbornMESH : NADPH-Ferrihemoprotein ReductaseMESH: Substrate SpecificityMESH : AnimalsNAD+ kinaseMESH : Cell Shape[SDV.AEN]Life Sciences [q-bio]/Food and NutritionOxidative stress
researchProduct

S-nitrosylation of the death receptor fas promotes fas ligand-mediated apoptosis in cancer cells.

2011

International audience; BACKGROUND & AIMS: Fas belongs to the family of tumor necrosis factor receptors which induce apoptosis. Many cancer cells express Fas but do not undergo Fas-mediated apoptosis. Nitric oxide reverses this resistance by increasing levels of Fas at the plasma membrane. We studied the mechanisms by which NO affects Fas function. METHODS: Colon and mammary cancer cell lines were incubated with the NO donor glyceryl trinitrate or lipid A; S-nitrosylation of Fas was monitored using the biotin switch assay. Fas constructs that contained mutations at cysteine residues that prevent S-nitrosylation were used to investigate the involvement of S-nitrosylation in Fas-mediated cell…

MESH: NitroglycerinMESH: Signal TransductionTime FactorsMESH: Membrane MicrodomainsApoptosisMESH : Fas Ligand ProteinCytoplasmic partMESH: Lipid AFas ligandMiceNitroglycerin0302 clinical medicineMESH : Protein TransportMESH : FemaleMESH: AnimalsFADDLipid raft0303 health sciencesTumorbiologyColon CancerMESH : Lipid AMESH : BiotinylationGastroenterologyFas receptorMESH: Antigens CD95Protein TransportLipid AMESH : Colonic NeoplasmsMESH : Nitric OxideMESH : Nitric Oxide Donors030220 oncology & carcinogenesisColonic NeoplasmsDeath-inducing signaling complexFemale[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH : MutationMESH : TransfectionSignal TransductionMESH : Time FactorsMESH: Protein TransportFas Ligand ProteinMESH : Mammary Neoplasms ExperimentalMESH: MutationMESH: Cell Line TumorMESH: Mammary Neoplasms ExperimentalNitric OxideTransfectionCaspase 803 medical and health sciencesMembrane MicrodomainsCell Line TumorMESH : MiceAnimalsHumansBiotinylationNitric Oxide DonorsMESH: BiotinylationCysteinefas ReceptorMESH: MiceMESH : Protein Processing Post-Translational030304 developmental biologyMESH : Signal TransductionMESH: Colonic NeoplasmsMESH : CysteineMESH: HumansHepatologyMESH : Cell Line TumorMESH: ApoptosisMESH: TransfectionMESH : HumansMESH: Time FactorsMammary Neoplasms Experimental[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyMESH: CysteineMESH: Nitric Oxide DonorsMolecular biologySignalingMESH: Fas Ligand ProteinMESH : NitroglycerinApoptosisLocalizationMESH: Nitric OxideMESH: Protein Processing Post-TranslationalMutationbiology.proteinMESH : Membrane MicrodomainsMESH : AnimalsMESH : Antigens CD95Protein Processing Post-TranslationalMESH: FemaleMESH : Apoptosis
researchProduct

Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colore…

2016

IF 2.415; International audience; The haemoglobin concentration measured by faecal immunochemical tests (FIT) may be decreased in cases of delayed sample return or high temperature. It is an issue of great importance. The aim of this study was to investigate the effects of sample return time and of season on the performance of an FIT (FOB-Gold) with a new buffer. The study included 20 371 participants involved in the French organized colorectal cancer (CRC) screening programme. The probability of a positive screening test, detection rates and positive predictive values for CRC and advanced adenoma were analysed according to sample return time and season of screening. A sample of positive FI…

MaleCancer ResearchMultivariate analysisTime FactorsEpidemiologyColorectal cancerMESH: Reagent Kits DiagnosticMESH : AgedMESH : HemoglobinsMESH : Early Detection of Cancer[ SDV.CAN ] Life Sciences [q-bio]/CancerReturn timeScreening programmeImmunoenzyme TechniquesHemoglobinsMESH : Specimen HandlingMESH : FemaleMESH : Neoplasm StagingMESH : Reagent Kits DiagnosticMESH : TemperatureEarly Detection of CancerMESH: AgedMESH: Middle AgedMESH : PrognosisTemperatureMESH: Follow-Up StudiesMESH: Neoplasm StagingMiddle AgedPrognosisPredictive valueMESH: TemperatureMESH: HemoglobinsMESH : Occult BloodOncologyColorectal cancer screeningOccult BloodFemaleSeasonsMESH : Colorectal NeoplasmsColorectal NeoplasmsMESH : Time FactorsAdenomamedicine.medical_specialtySample (material)MESH : Male[SDV.CAN]Life Sciences [q-bio]/CancerMESH: PrognosisSpecimen HandlingAnimal scienceMESH : Immunoenzyme TechniquesmedicineHumansMESH: Early Detection of CancerMESH : Middle AgedMESH: Specimen HandlingMESH: Immunoenzyme TechniquesAgedNeoplasm StagingMESH: AdenomaMESH: HumansMESH : Seasonsbusiness.industryMESH: Time FactorsMESH : HumansPublic Health Environmental and Occupational HealthMESH : Follow-Up Studiesmedicine.diseaseMESH: MaleSurgeryMESH : AdenomaReagent Kits DiagnosticFaecal occult blood testbusinessMESH: Occult BloodMESH: FemaleMESH: SeasonsMESH: Colorectal NeoplasmsFollow-Up Studies
researchProduct

Medical pre-hospital management reduces mortality in severe blunt trauma: a prospective epidemiological study

2011

International audience; INTRODUCTION: Severe blunt trauma is a leading cause of premature death and handicap. However, the benefit for the patient of pre-hospital management by emergency physicians remains controversial because it may delay admission to hospital. This study aimed to compare the impact of medical pre-hospital management performed by SMUR (Service Mobile d'Urgences et de Réanimation) with non-medical pre-hospital management provided by fire brigades (non-SMUR) on 30-day mortality. METHODS: The FIRST (French Intensive care Recorded in Severe Trauma) study is a multicenter cohort study on consecutive patients with severe blunt trauma requiring admission to university hospital i…

MaleEmergency Medical ServicesTime FactorsMESH : AgedMESH : Prospective StudiesPoison controlCritical Care and Intensive Care Medicine0302 clinical medicineInjury Severity ScorePatient AdmissionEmergency medical services[ SHS.INFO ] Humanities and Social Sciences/Library and information sciences030212 general & internal medicineHospital MortalityProspective StudiesProspective cohort studyMESH: Treatment OutcomeMESH: AgedMESH: Middle AgedMortality rate[ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologieMESH : Patient AdmissionMESH : AdultMiddle Aged3. Good healthMESH : Wounds and InjuriesIntensive Care UnitsTreatment OutcomeBlunt traumaMESH: Young AdultBlunt traumaMESH: Emergency Medical ServicesInjury Severity ScoreMESH : Injury Severity ScoreFranceMESH: FirefightersMESH : Intensive Care UnitsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyAdolescentMESH : Male[SHS.INFO]Humanities and Social Sciences/Library and information sciencesMESH: Injury Severity ScoreMESH : Young AdultMESH : Treatment Outcome[SHS.INFO] Humanities and Social Sciences/Library and information sciencesMESH : Hospital Mortality03 medical and health sciencesYoung AdultIntensive careMESH : AdolescentmedicineHumansMESH : Emergency Medical ServicesMESH : Middle AgedMESH: Hospital MortalityIntensive care medicineMESH : FranceAgedMESH: AdolescentMESH: Humansbusiness.industryMESH: Patient AdmissionResearchMESH : HumansMESH: Time Factors030208 emergency & critical care medicineMESH: AdultMESH: MaleMESH: Prospective StudiesMESH: France[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieMESH: Wounds and InjuriesFirefightersEmergency medicineWounds and InjuriesMESH: Intensive Care Units[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH : FirefightersbusinessCritical Care
researchProduct

Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: The 2005 French FAST-MI study.

2016

IF 2.271; International audience; Background. - Clinical studies have shown a beneficial effect of cardiac rehabilitation (CR) on mortality.Objective. - To study the effect of CR prescription at discharge on 5-year mortality in patients with acute myocardial infarction (AMI).Methods. - Participants, from the 2005 French FAST-MI hospital registry, were 2894 survivors at discharge, divided according to AMI type: ST-segment elevation myocardial infarction (STEMI; n=1523) and non-STEMI (NSTEMI; n=1371). The effect of CR prescription on mortality was analysed using a Cox proportional hazards model.Results. - At discharge, 22.1% of patients had a CR prescription. Patients referred to CR were youn…

MaleMESH: Chi-Square Distributionmedicine.medical_treatmentMESH : Acute Coronary SyndromeMyocardial InfarctionMESH : AgedMESH : Prospective StudiesCardiac rehabilitationMESH: Risk Assessment0302 clinical medicineMyocardial infarctionProspective StudiesReferral and ConsultationMESH: Treatment OutcomeRehabilitationMESH: Middle AgedGeneral MedicineMESH: Follow-Up Studies3. Good healthMESH: Myocardial InfarctionMESH : Patient DischargeCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute myocardial infarctionMortalitéRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedAcute Coronary SyndromeMESH: Kaplan-Meier EstimateAgedChi-Square DistributionMESH: HumansMESH : Chi-Square DistributionProportional hazards modelMESH: Patient DischargeMESH : HumansPatient survivalMESH : Follow-Up Studiesmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Acute Coronary SyndromeST-segment elevation myocardial infarctionMESH: FemaleTime FactorsMESH: RegistriesKaplan-Meier Estimate030204 cardiovascular system & hematologyMESH : Referral and ConsultationMESH: Proportional Hazards ModelsOlder patientsRisk FactorsMESH: Risk FactorsMESH : Female030212 general & internal medicineRegistriesMESH : Risk AssessmentMESH: AgedEjection fractionNon–ST-segment elevation myocardial infarctionMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsPatient DischargeTreatment OutcomeFemaleFranceMESH : Time FactorsMESH : MaleMESH : Treatment OutcomeMESH: Multivariate AnalysisMESH : Kaplan-Meier EstimateMESH: Referral and ConsultationInternal medicineInfarctus du myocarde sans sus-décalage du segment STmedicineIn patientcardiovascular diseasesMedical prescriptionMortalityRéadaptation cardiaqueMESH : FranceProportional Hazards Modelsbusiness.industryInfarctus du myocarde avec sus-décalage du segment STMESH: Time FactorsMESH : Multivariate AnalysisMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceInfarctus du myocarde aiguMultivariate AnalysisMESH : Myocardial InfarctionbusinessMESH : RegistriesFollow-Up Studies
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

Incremental predictive value of mean platelet volume/platelet count ratio in in-hospital stroke after acute myocardial infarction.

2017

IF 2.558; International audience; Stroke is a serious complication after acute myocardial infarction (AMI) and is associated with an increased risk of death. Though the pathophysiological mechanisms are not exactly known, increased inflammation and platelet reactivity could play an important role in the occurrence of stroke during AMI. We aimed to investigate the relationship between both mean platelet volume (MPV), a parameter of platelet function, and C-reactive protein (CRP) and the occurrence of in-hospital ischemic stroke (IHS) after AMI. Data were obtained from a French regional survey for AMI that included 5976 patients admitted to an intensive care unit (ICU) between 2001 and 2010. …

MaleTime FactorsMESH : StrokeMyocardial InfarctionMESH : AgedMESH: ComorbidityComorbidityMESH: Hospitalization030204 cardiovascular system & hematologyMESH : Platelet Countlaw.inventionMESH: Proportional Hazards Models0302 clinical medicineMESH: Aged 80 and overRisk FactorslawMESH: Risk FactorsOdds Ratio[ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/HematologyMESH : FemaleMyocardial infarctionMESH : BiomarkersStrokeMESH: Blood PlateletsAged 80 and overMESH: AgedEjection fractionMESH: Middle AgedMESH : PrognosisbiologyMESH : Mean Platelet Volume[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyHematologyGeneral MedicineMiddle AgedPrognosisIntensive care unitstrokeMESH : Risk Factors3. Good healthHospitalizationMESH: Myocardial Infarctionrisk factorplateletsMESH : ComorbidityCardiologyMESH : HospitalizationFemaleMean Platelet VolumeMESH : Time FactorsBlood Plateletsmedicine.medical_specialtyMESH : Male[SDV.BC]Life Sciences [q-bio]/Cellular BiologyAcute myocardial infarctionMESH: PrognosisMESH: StrokeC-reactive protein03 medical and health sciencesInternal medicinemedicineHumansMESH : Middle AgedMESH: Platelet Countcardiovascular diseasesRisk factorMean platelet volumeMESH : Aged 80 and overSurvival analysisAgedProportional Hazards ModelsMESH: HumansPlatelet Countbusiness.industry[ SDV.BC ] Life Sciences [q-bio]/Cellular BiologyC-reactive proteinMESH: Time FactorsMESH : HumansMESH : Blood Plateletsmedicine.diseaseMESH : Proportional Hazards ModelsMESH: Odds RatioMESH: MaleMESH: Mean Platelet Volumebiology.proteinMESH: BiomarkersMESH : Odds RatioMESH : Myocardial InfarctionbusinessMESH: FemaleBiomarkers030217 neurology & neurosurgery
researchProduct

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

2010

Abstract Background Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have been validated in digestive oncology. The aim of this study was to draw up an ordered list of potential surrogate endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists. Secondary objective was to obtain their opinion on surrogacy and quality of life (QoL). Methods In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and methodologists involved in the conduct of …

OncologyCancer ResearchTime FactorsDigestive System Neoplasms[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of lifeSurveys and QuestionnairesMedicine030212 general & internal medicineMESH: Treatment OutcomeResponse rate (survey)MESH : Evidence-Based MedicineClinical Trials as TopicEvidence-Based MedicineMESH: Endpoint DeterminationMESH: Research DesignMESH : QuestionnairesMESH : Research Designlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMESH: Reproducibility of Resultsmedicine.anatomical_structureTreatment OutcomeOncologyResearch Design030220 oncology & carcinogenesisData Interpretation StatisticalMESH: Survival AnalysisMESH : Disease-Free SurvivalMESH : Endpoint DeterminationFranceMESH : Time FactorsResearch Articlemedicine.medical_specialtyMESH: Clinical Trials as TopicEndpoint DeterminationRectum[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Treatment Outcomelcsh:RC254-282Disease-Free Survival03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneticsHumansMESH : Data Interpretation StatisticalMESH : FranceSurvival analysisMESH: Humansbusiness.industrySurrogate endpointMESH: Digestive System NeoplasmsMESH : Reproducibility of ResultsMESH: QuestionnairesMESH : HumansMESH: Time FactorsCancerReproducibility of ResultsMESH: Quality of LifeMESH : Quality of Lifemedicine.diseaseSurvival AnalysisMESH : Clinical Trials as TopicMESH: FranceLocalized diseaseEndpoint DeterminationMESH: Disease-Free SurvivalQuality of LifeMESH : Digestive System NeoplasmsMESH : Survival AnalysisbusinessMESH: Data Interpretation StatisticalMESH: Evidence-Based MedicineBMC Cancer
researchProduct